Please ensure Javascript is enabled for purposes of website accessibility

5 Charts That Explain Why Canopy Growth Is My Favorite Marijuana Stock

By Todd Campbell - Feb 22, 2018 at 8:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This cannabis company could be the best in the business.

Canopy Growth (CGC 4.72%) is Canada's biggest marijuana company, and its sales could skyrocket once Canada's recreational marijuana market opens for business. Are this company's best days ahead of it? Here are five charts that show why I think the answer to that question is yes.

Chart No. 1: Cannabis consumers on the rise

According to Health Canada, the number of medical marijuana licenses in Canada has climbed to over 230,000, and as a result, Canopy Growth is serving more people than ever.

Marijuana growing in pots in a greenhouse.


In its most recent quarter, Canopy Growth sold medical marijuana products, including oils and soft-gel capsules, to 69,000 people, more than double the number it sold to in the same quarter one year ago. Over time, Health Canada -- the nation's marijuana regulator -- thinks 450,000 patients could be using medical cannabis. If that forecast is correct, then a lack of demand shouldn't be a problem for this company.

A bar chart showing ascending patient growth.

Author's chart.

Chart No. 2: Big money at stake

Canopy Growth has an opportunity to sell more medical marijuana to more patients, but it also has a much bigger opportunity to sell marijuana to recreational users.

The company's 30% plus medical marijuana market share could indicate it has the brand recognition necessary to win recreational market share when Canada's recreational market opens for business this summer. Estimates for how big of an opportunity Canada's recreational market could be vary, but CIBC World Markets thinks it could exceed $5 billion. If it's anywhere near that big, it would dwarf Canada's medical marijuana market, which GreenWave Advisors' Matt Karnes estimates was approximately $2 billion last year.

A pie chart showing how much bigger the recreational marijuana market may be than the medical marijuana market in Canada.

Data source: CIBC World Markets & GreenWave Advisors. Author's chart.

Chart No. 3: Production preparation

Serving a much larger recreational market will require significantly more production capacity. Fortunately, Canopy Growth has made big investments to expand marijuana production, and that's translating into significantly larger marijuana harvests. Last quarter, its marijuana harvest was up 51.2% year over year.

With 600,000 square feet of licensed indoor and greenhouse production capacity already, and plans for up to 5 million additional square feet in the works, I think Canopy Growth should be able to meet the expected increase in demand from recreational marijuana users.

A bar chart showing that harvests are increasing in size.

Author's chart.

Chart No. 4: Rising revenue

The Canadian marijuana market is growing quickly, but Canopy Growth faces stiff competition that could chip away at its revenue.

For example, Aurora Cannabis (ACB 7.75%) and Aphria Inc. (NASDAQOTH: APHQF) are two of its biggest competitors, and each is making investments to increase their grow capacity. Aurora expects to complete an 800,000-square-foot expansion by the middle of this year, and Aphria expects to have 1 million square feet up and running early this year. However, those competitors' efforts have yet to crimp Canopy Growth's revenue. In its recently reported fiscal third quarter of 2018, sales climbed 123% to 21.7 million Canadian dollars.

WEED Revenue (TTM) Chart

WEED Revenue (TTM) data by YCharts.

Chart No. 5: Producing a profit

Canopy Growth's focus has been on investing for future growth, not delivering shareholder-friendly earnings per share. That may change later this year, though. During an interview with the Motley Fool last year, Canopy Growth's CEO suggested the company should be able to focus more on profitability once recreational cannabis orders begin rolling in.

One reason Canopy Growth's earnings could become meaningful at that point is its operating leverage. As sales and harvests have increased, its cost of production has fallen. Not including shipping and fulfillment expenses, average weighted production costs were only $1.03 per gram last quarter, down from $1.41 per gram a year ago. This allowed the company to report net earnings of $11,014 million Canadian, $0.01 per share, last quarter, in spite of its spending to expand its licensed square feet of production space.

A bar chart showing falling costs per gram for producing marijuana.

Author's chart.

Overall, Canopy Growth is enjoying rapid demand growth, and so far, it's been able to meet that demand and generate significant sales. Its investments to increase marijuana production and lower production costs suggest it could be very well positioned to profit from recreational marijuana sales later this year, and that's why Canopy Growth is my favorite marijuana stock to buy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Canopy Growth Stock Quote
Canopy Growth
$3.77 (4.72%) $0.17
Aurora Cannabis Stock Quote
Aurora Cannabis
$1.53 (7.75%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.